Comparative Pharmacology
Head-to-head clinical analysis: PRED MILD versus PRED G.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRED MILD versus PRED G.
PRED MILD vs PRED-G
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Prednisolone acetate is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2 and reduction of inflammatory mediators such as prostaglandins and leukotrienes.
Prednisolone acetate is a glucocorticoid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; gentamicin sulfate is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to 30S ribosomal subunit.
Treatment of steroid-responsive inflammatory conditions of the eye (e.g., allergic conjunctivitis, keratitis, iritis)
Steroid-responsive inflammatory ocular conditions where bacterial infection or risk of infection existsBlepharitisConjunctivitisKeratitisIritisIridocyclitis
1 to 2 drops in the affected eye(s) every hour during the day and every 2 hours at night until a favorable response is obtained, then reduce to 1 drop every 4 hours, and later to 1 drop 3 to 4 times daily as needed to control symptoms.
1 drop of the ophthalmic suspension (containing prednisolone acetate 1% and gentamicin sulfate 0.3%) into the affected eye(s) every 2-4 hours during the day, then taper as clinical signs improve. For severe disease, 1 drop every hour initially.
None Documented
None Documented
The terminal elimination half-life of prednisolone is approximately 2.1-3.5 hours. Clinically, this short half-life supports once-daily dosing for many conditions, with minimal accumulation upon repeated administration.
The terminal elimination half-life of gentamicin (the active component) is approximately 2–3 hours in adults with normal renal function. In neonates, half-life is prolonged to 5–11 hours. The immunosuppressive component (prednisolone) has a half-life of 2–4 hours.
Primarily hepatic via CYP3A4; major metabolite is prednisolone (active form of prednisone).
Prednisolone undergoes hepatic metabolism primarily via CYP3A4; gentamicin is excreted unchanged in urine.
Prednisolone is primarily excreted renally, with approximately 70-80% of the dose eliminated as metabolites in urine (including glucuronides and sulfates) and less than 10% as unchanged drug. Biliary/fecal excretion accounts for about 20% of the dose.
Renal excretion accounts for approximately 70% of elimination, with the remainder as unchanged drug in feces (20%) and biliary excretion (10%).
Prednisolone is approximately 70-90% bound to plasma proteins, primarily to corticosteroid-binding globulin (CBG) and, to a lesser extent, albumin.
Gentamicin: less than 30% bound to plasma proteins. Prednisolone: approximately 70–90% bound to corticosteroid-binding globulin and albumin.
The volume of distribution (Vd) of prednisolone is approximately 0.4-0.6 L/kg. This suggests moderate distribution into tissues, with a Vd approximately equal to total body water, indicating not extensive tissue binding.
Gentamicin: 0.2–0.3 L/kg, indicating distribution primarily into extracellular fluid. Prednisolone: 0.4–1.0 L/kg, reflecting extensive tissue distribution.
Oral bioavailability of prednisolone is approximately 70-80%. This high bioavailability is due to its rapid and nearly complete absorption from the gastrointestinal tract.
Ophthalmic suspension: systemic bioavailability is minimal (<1%) due to small dose and rapid clearance, but can be higher if nasolacrimal occlusion is not used.
No dose adjustment required for renal impairment.
No systemic absorption occurs with ophthalmic use; thus, no renal adjustment is required. Gentamicin component may have renal effects if absorbed, but topical ocular use does not necessitate GFR-based modifications.
No dose adjustment required for hepatic impairment.
No systemic absorption occurs; no adjustment required for hepatic impairment.
Safety and efficacy in pediatric patients have not been established. Use only if potential benefit outweighs risk.
Same as adult dosing: 1 drop of ophthalmic suspension into the affected eye(s) every 2-4 hours, tapering as response allows. Safety and efficacy established in children; no weight-based dosing necessary due to topical administration.
No specific dose adjustment recommended, use with caution due to increased risk of intraocular pressure elevation and cataract formation.
No specific dose adjustment needed. Use same dosing as adults. Monitor for increased intraocular pressure (IOP) due to steroid component; elderly may be more susceptible to IOP elevation and cataract formation.
None
None
["Prolonged use may lead to cataracts, glaucoma, secondary ocular infections, and delayed wound healing.","Use caution in patients with corneal thinning.","Avoid abrupt discontinuation after long-term use."]
["Prolonged use may lead to ocular hypertension/glaucoma, optic nerve damage, cataract formation","May mask infection or promote secondary infection","Fungal infections should be considered in persistent corneal ulceration","Not for injection","Cross-sensitivity to other aminoglycosides possible"]
["Uncontrolled ocular infections (e.g., fungal, viral, bacterial, or mycobacterial)","Known hypersensitivity to prednisolone or any component."]
["Hypersensitivity to prednisolone, gentamicin, or any component","Epithelial herpes simplex keratitis (dendritic keratitis)","Vaccinia, varicella, and other viral infections of cornea/conjunctiva","Mycobacterial infections of eye","Fungal infections of ocular structures"]
Data Pending Review
Data Pending Review
No significant food interactions reported for ophthalmic use.
None reported for ophthalmic use.
First trimester: Increased risk of orofacial clefts (odds ratio 1.3-3.4) with systemic use; no data for topical prednisolone acetate 0.12% (PRED MILD) due to negligible systemic absorption. Second/third trimesters: Risk of fetal adrenal suppression with prolonged high-dose systemic corticosteroids, but not expected with topical ophthalmic use. Overall risk considered low based on minimal systemic exposure.
PRED-G (prednisolone acetate 1% and gentamicin sulfate 0.3% ophthalmic suspension) is classified as FDA Pregnancy Category C. Topical ophthalmic use results in minimal systemic absorption; however, corticosteroids are generally associated with an increased risk of cleft palate and intrauterine growth restriction when used systemically during the first trimester. Gentamicin has been associated with fetal ototoxicity and nephrotoxicity with prolonged systemic use. Overall risk from ophthalmic administration is considered low, but caution is advised.
Prednisolone enters breast milk in low amounts. M/P ratio not established for ophthalmic formulation; systemic prednisolone M/P ratio is approximately 0.4-0.6. Topical ocular use results in negligible systemic absorption; risk to infant is considered minimal. Compatible with breastfeeding.
Systemic absorption following topical ophthalmic administration is negligible. Prednisolone is excreted into breast milk in low amounts; gentamicin is also excreted in low concentrations. The M/P ratio for prednisolone is approximately 0.5-2.0 (estimated from systemic use). Given the low ocular dose, it is considered compatible with breastfeeding. Monitor infant for gastrointestinal effects (gentamicin) and adrenal suppression (prednisolone) if prolonged use.
No dose adjustment required for ophthalmic prednisolone acetate 0.12% during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) are not clinically significant due to negligible systemic absorption.
No dose adjustment is generally required for topical ophthalmic administration during pregnancy as systemic absorption is minimal. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, altered metabolism) do not affect local drug concentration. Use the same dose as in non-pregnant patients, but limit duration and frequency as clinically appropriate.
Category C
Category C
Pred Mild (prednisolone acetate) is a mild corticosteroid ophthalmic suspension used for ocular inflammation. Shake well before use; do not use for viral or fungal infections; monitor for increased intraocular pressure with prolonged use; taper dose if discontinuing after long-term therapy.
PRED-G is a combination of prednisolone acetate (corticosteroid) and gentamicin (aminoglycoside antibiotic) used for ophthalmic inflammatory conditions with bacterial infection or risk of infection. Shake vigorously before each use. Do not use in viral, fungal, or mycobacterial ocular infections. Intraocular pressure should be monitored regularly with prolonged use. Avoid contamination of the dropper tip. Use with caution in patients with corneal thinning or glaucoma.
Shake the bottle vigorously before each use.Do not touch the dropper tip to any surface to avoid contamination.Wash hands before and after instillation.Wait 5 minutes between different eye drops if using multiple.Do not use for eye infections caused by viruses or fungi.Report any vision changes, eye pain, or worsening redness.Do not stop suddenly if used long-term; follow tapering instructions.Store at room temperature, away from heat and light.Do not use beyond expiration date.
Shake the bottle well before each use.Wash hands before applying the drops.Do not touch the dropper tip to any surface to avoid contamination.Tilt head back, pull down lower eyelid, and apply the prescribed number of drops.Close eyes gently for 1-2 minutes after instillation.Do not use while wearing contact lenses unless directed by your doctor.Report any vision changes, eye pain, or worsening redness immediately.Complete the full course as prescribed; do not stop abruptly without consulting your doctor.Keep out of reach of children.